Prasugrel – co wiemy w roku 2010? Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2010
Słowa kluczowe:
prasugrel, klopidogrel, ostry zespół wieńcowy, badanie TRITON TIMI 38
##plugins.themes.bootstrap3.article.main##
Abstrakt
Podwójna terapia przeciwpłytkowa złożona z aspiryny i tienopirydyny jest obecnie podstawą w zapobieganiu powikłaniom zakrzepowym u chorych z ostrymi zespołami wieńcowymi (OZW). Klopidogrel jest zaakceptowanym standardem postępowania u chorych z OZW. Prasugrel to nowy lek z grupy tienopirydyn, który w porównaniu z klopidogrelem w większym stopniu zapobiega nowym i ponownym zawałom serca u chorych z rozpoznaniem OZW leczonych pierwotną angioplastyką wieńcową. Skuteczność prasugrelu po raz pierwszy udowodniono w opublikowanym w 2007 roku badaniu TRITON TIMI 38. Do chwili obecnej ukazało się wiele subanaliz badania TRITON. W poniższym artykule zostały przedstawione pochodzące z nich nowe dane dotyczące prasugrelu.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Janiszewski , M., & Chmielewski , M. (2010). Prasugrel – co wiemy w roku 2010? . Medycyna Faktów , 3(2(7), 57-61. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2605
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Wiviott S.D., Trenk D., Frelinger A.L. et al. (for the PRINCIPLE-TIMI 44 Investigators): Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention. The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 Trial. Circulation 2007; 116: 2923-2932.
2. Wiviott S.D., Braunwald E., McCabe C.H. et al. (for the TRITON–TIMI 38 Investigators): Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N. Engl. J. Med. 2007; 357: 2001-15.
3. Wiviott S.D., Braunwald E., Angiolillo D.J. et al.: Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008 Oct 14; 118(16): 1626-36.
4. Antman E.M., Wiviott S.D., Murphy A.S. et al.: Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention A TRITON–TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) Analysis. J. Am. Coll. Cardiol. 2008; 51: 2028-2033.
5. Pride Y.B., Wiviott S.D., Buros J.L. et al.: Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy. Am. Heart J. 2009 Sep; 158(3): e21-6.
6. Morrow D.A., Wiviott S.D., White H.D. et al.: Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel- Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 2009 Jun 2; 119(21): 2758-64.
7. Mahoney E.M., Wang K., Arnold S.V. et al.: Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation 2010 Jan 5; 121(1): 71-9.
2. Wiviott S.D., Braunwald E., McCabe C.H. et al. (for the TRITON–TIMI 38 Investigators): Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N. Engl. J. Med. 2007; 357: 2001-15.
3. Wiviott S.D., Braunwald E., Angiolillo D.J. et al.: Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008 Oct 14; 118(16): 1626-36.
4. Antman E.M., Wiviott S.D., Murphy A.S. et al.: Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention A TRITON–TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) Analysis. J. Am. Coll. Cardiol. 2008; 51: 2028-2033.
5. Pride Y.B., Wiviott S.D., Buros J.L. et al.: Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy. Am. Heart J. 2009 Sep; 158(3): e21-6.
6. Morrow D.A., Wiviott S.D., White H.D. et al.: Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel- Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 2009 Jun 2; 119(21): 2758-64.
7. Mahoney E.M., Wang K., Arnold S.V. et al.: Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation 2010 Jan 5; 121(1): 71-9.